⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21238558 | 1.00 | — | — | |
| SCHEMBL12946059 | 0.88 | MGLL (0.31) | — | |
| SCHEMBL18295452 | 0.85 | ELOVL1 (0.32) | — | |
| SCHEMBL16846392 | 0.81 | — | — | |
| SCHEMBL15451900 | 0.79 | KDM4E (0.32) | — | |
| SCHEMBL20688088 | 0.79 | KDM4E (0.32) | — | |
| SCHEMBL22594113 | 0.79 | — | — | |
| SCHEMBL14388346 | 0.79 | DRD4 (0.36) | — | |
| SCHEMBL12832227 | 0.78 | LRRK2 (0.31) | — | |
| SCHEMBL24022478 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| WO-2023121413-A1 | NOVEL BICYCLIC HETEROCYCLYL COMPOUND AND USE THEREOF | 제일약품주식회사 | 2023-06-29 | — | — | WO | disclosed |
| US-11377444-B2 | Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2022-07-05 | — | — | US | disclosed |
| US-20200339568-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | MEDSHINE DISCOVERY INC. (CN) | 2020-10-29 | — | — | US | disclosed |
| EP-3712157-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | Medshine Discovery Inc. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-9751873-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160168141-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2015104353-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015104356-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |